Bristol Myers Squibb Invests $2.3 Billion in Houston Campus
The investment furthers the company's $40 billion commitment to invest in American innovation and manufacturing.
Bristol Myers Squibb announced Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. The campus will create nearly 500 skilled jobs and is designed to grow.
The selection of Houston marks a significant milestone in BMS’ $40 billion commitment to invest in the United States over five years across research and development, technology and domestic manufacturing.
The campus has a modular design that allows BMS to add and reconfigure manufacturing capacity as needed. Its multi-modal capabilities will manufacture multiple types of medicines - such as small molecules, biologics, and antibody-drug conjugates - across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch. This flexibility ensures the campus can evolve to meet patient needs well into the future.
"This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation,” said Christopher Boerner, Board Chair and CEO of Bristol Myers Squibb. “As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."
"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” said Karin Shanahan, EVP, Chief Supply Chain and Operations Officer of Bristol Myers Squibb. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”
Bristol Myers Squibb’s approximately 600,000-square-foot manufacturing campus in Houston, Texas, will be a modular, multi-modal campus designed for flexibility and long-term growth. Its architecture allows new manufacturing capabilities to be brought online rapidly as pipeline and commercial needs evolve. The campus is also built for adaptability, with configuration flexibility that anticipates future advances in digital integration and automation, ensuring the site remains at the frontier of biopharmaceutical development and manufacturing technology as capabilities continue to evolve.
